Anebulo Pharmaceuticals (ANEB) Q1 2025 Earnings Report

Anebulo Pharmaceuticals reported QQ1 2025 results with no revenue and a continued cash burn driven by research and development and general and administrative expenses. Key profitability metrics remained negative, with EBITDA of -$2.141 million and a net loss of -$2.201 million for the quarter. R&D expenses totaled $1.315 million and G&A totaled $1.097 million, contributing to an operating loss of $2.412 million. The company generated negative free cash flow of -$1.689 million, leaving a cash balance of approximately $2.404 million at period end and a net cash position near $1.404 million (no debt reported). Liquidity metrics remain favorable on a relative basis (current ratio ~3.45), but the business is heavily cash-burn dependent with an extremely limited near-term runway absent additional financing.

Strategically, Anebulo remains focused on its lead candidate ANEB001 for cannabinoid intoxication and overdose, a high-need clinical area. With no revenue to support ongoing development, execution hinges on successful clinical progress, strategic partnerships, or capital markets activity to extend the runway. Management commentary and forward guidance are not provided in the disclosed materials, creating a need for catalysts such as clinical readouts, partnership discussions, or financing updates to recalibrate risk and value. The magnitude of the accumulated deficit and reliance on external funding underscore the importance of near-term liquidity management and a clear clinical-value proposition to attract partnering opportunities or alternative financing arrangements.